Product Center
-
The Launch Meeting of Phase I/II Clinical Trial for Recombinant Herpes Zoster Vaccine (CHO Cell) was successfully held
2025-02-18Recently, the Phase I/II clinical trial launch meeting for the recombinant herpes zoster vaccine (CHO cell), co-developed by Ab&B Bio-Tech CO., LTD. JS. and Yither Biotech (Shanghai) Co., Ltd., was successfully held in Henan, and the first-in-human (FIH) dosing was successfully completed.
Read More -
Ab&B Bio and Yither Bio Have Both Obtained Qualification Certification!
2024-12-30Recently, Ab&B Bio-Tech Co., Ltd. (Ab&B Bio) and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) have been recognized as a Jiangsu Province Specialized and Innovative Small and Medium-Sized Enterprise and a National High-Tech Enterprise, respectively.
Read More -
Kickoff Meeting for Clinical Research on Quadrivalent Influenza Virus Subunit Vaccine in Children with Nephrotic Syndrome Successfully Held
2024-12-25Recently, the clinical launch meeting for the immunogenicity and safety of quadrivalent influenza virus subunit vaccine for children with nephrotic syndrome, in collaboration with Ab&B Bio-Tech Co.,Ltd（Ab&B Bio） was successfully held at the research site in Guangdong. This clinical study is sponsored and conducted by the Guangzhou Women and Children's Medical Center as the lead research unit, aiming to provide evidence-based influenza vaccination guidelines for children with nephrotic syndrome as a special population, thereby reducing their risk of influenza virus infection and severe complications.
Read More -
IND Application for Influenza Virus Subunit Vaccine (Adjuvanted) Approved
2024-10-30Recently, Ab&B Bio-Tech Co., Ltd. (Ab&B Bio) and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) jointly submitted an Investigational New Drug (IND) application for a Class I new drug—the "Influenza Virus Subunit Vaccine (Adjuvanted)"—which has been approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA). This approval marks the completion of the company’s full pipeline coverage for subunit influenza vaccines, including both trivalent and quadrivalent formulations, offering tailored options for diverse age groups and populations with specific needs.
Read More
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
